Zeitschrift für Lungenkrankheiten und -behandlung

Montelukast Suspected Adverse Reaction in Children

Abstract

Sumayyah AlKhater

Leukotriene receptor antagonist (LTRA) montelukast is frequently used for breathing difficulties associated with sleep, allergic rhinitis, and asthma. Recent investigations have documented a number of negative outcomes in kids, including neuropsychiatric problems and sleep difficulties. Objective: To learn more about the safety profile of montelukast for kids with allergies, hay fever, and breathing problems related to sleep. Method and findings: Over a two-year period, we retrospectively examined all adverse medication reactions to montelukast among 385 kids aged 6 months and older in six tertiary centres. 89.6% of patients had asthma, 50% had allergic rhinitis, and 13.6% had breathing problems linked to sleep. Singulair was the most widely used form of montelukast, accounting for 67.9% of all prescriptions. According to this study, there were 123 individuals who experienced adverse medication responses, and the majority of them were in those toddlers (22.8%) and those between the ages of 4 and 9 (52.8%) were the next two age groups. 9.8% of the children had two (ADRs) documented, whereas 5.5% had three or more. The most frequent adverse drug reactions (ADRs), which affected 15.1% of participants (overlap was widespread; 5.5% of kids had trouble sleeping, 4.4% had trouble falling asleep or staying asleep, and 1.82% had nightmares), were agitation (10.4%), pain (9.4%), and hyperactivity (6.8%).